The analysis showed that the benefit in ESCC was higher in the case of PD-L1 CPS ≥ 10 (HR: 0.60 versus 0.83 in PD-L1 < 10, p = 0.009), suggesting a promising role for PD-L1 as molecular biomarkers in ESCC. Here, CD274 is linked to esophageal squamous cell carcinoma.